

CLEARBRIDGE HEALTH LIMITED
(Company Registration No.: 201001436C)
(Incorporated in the Republic of Singapore)

NON-EXCLUSIVE AGREEMENT TO DISTRIBUTE BIOLIDICS' COVID-19 ANTIBODY TEST KITS

The board of directors (the "**Board**" or the "**Directors**") of Clearbridge Health Limited (the "**Company**") and together with its subsidiaries, the "**Group**") is pleased to announce that Clearbridge Medical Group Pte. Ltd. ("**CBMG**"), a wholly-owned subsidiary of the Company, had on 11 May 2020, entered into a distribution agreement (the "**Agreement**") with Biolidics Limited ("**Biolidics**"), pursuant to which Biolidics has appointed CBMG as a non-exclusive distributor for Biolidics' test kits for the detection of the Novel Coronavirus 2019 antibodies (the "**COVID-19 Antibody Test Kits**"), in the Philippines, Indonesia, Myanmar and Vietnam (the "**Territories**") for a duration of one year from the date of the Agreement. The COVID-19 Antibody Test Kits are for the qualitative detection of the antibodies to SARS-CoV-2 (the virus which causes the COVID-19 disease), IgG and IgM, in human serum, plasma and whole blood.

Pursuant to the terms of the Agreement, among others, CBMG shall (a) assist Biolidics in obtaining all permits, licenses, registrations and consents from the applicable authorities in order to import and sell the COVID-19 Antibody Test Kits in the Territories, and (b) upon request by Biolidics, arrange for appropriate trials and demonstrations of the COVID-19 Antibody Test Kits in the Territories to promote the sale of the COVID-19 Antibody Test Kits. The use of the COVID-19 Antibody Test Kits in the Territories will be limited to testing in laboratories or by healthcare workers at the point-of-care.

Biolidics is a precision medicine medical technology company focused on developing a portfolio of innovative diagnostic solutions and is listed on the Catalist Board of the Singapore Exchange Securities Trading Limited. As at the date of this announcement, the Company is a controlling shareholder of Biolidics and holds a deemed interest of approximately 33.04% in Biolidics. The Agreement was entered into pursuant to a general mandate that Biolidics obtained at its general meeting held on 30 April 2020 to enter into certain recurrent transactions with certain entities within the Group, including the provision of distribution services by such entities for the distribution of medical and healthcare products and services to customers in Singapore and overseas.

The Agreement is likely to contribute positively to the revenue of the Group for the current financial year ending 31 December 2020 ("**FY2020**"). However, the Company is unable to quantify the financial impact for FY2020 as it is unable to forecast or determine the demand for the COVID-19 Antibody Test Kits in the Territories.

Shareholders and potential investors should note that the distribution of Biolidics' COVID-19 Antibody Test Kits in the Territories is subject to the COVID-19 Antibody Test Kits obtaining the requisite permits, licenses, registrations and consents from the applicable authorities in the Territories ("**Regulatory Approvals**"). There is no certainty that such Regulatory Approvals, if required, will be obtained.

Shareholders and potential investors should note that policies in relation to diagnosis and/or detection of the COVID-19 virus and/or antibodies in various jurisdictions may change in response to

developments in the COVID-19 situation which is evolving rapidly. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take.

Except for Yee Pinh Jeremy and Chen Johnson who are directors of both the Company and Biolidics, and who did not participate in the decision-making in relation this Agreement, the Company is not aware of any of its Directors or substantial shareholders of the Company having any interest, direct or indirect, in the Agreement other than through their respective shareholding interests in the Company (if any) and Biolidics (if any).

BY ORDER OF THE BOARD

Andrew John Lord
Lead Independent Director

11 May 2020

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*